Drug Trial Radar · NCT04472429
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
308
Actual
Start
Nov 9, 2020
Primary completion
Apr 15, 2024
Study completion Sep 26, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 15, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Conditions
- Squamous Cell Carcinoma of the Anal Canal
Interventions
carboplatinDrug
carboplatin will be administered intravenous on Day 1 of each 28 day cycle
paclitaxelDrug
paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
retifanlimabDrug
retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: up to 33.9 months
Locations
84 sites in 13 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center
Tucson, Arizona
City of Hope National Medical Center
Duarte, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Sansum Clinic
Santa Barbara, California
Rocky Mountain Cancer Center
Denver, Colorado
Ochsner Clinic
New Orleans, Louisiana
Maryland Oncology Hematology, P.A.
Columbia, Maryland
Mayo Clinic
Rochester, Minnesota
Texas Oncology
Austin, Texas
Baylor Scott and White Research Institute
Dallas, Texas
Renovatio Clinical Consultants Llc
The Woodlands, Texas
Texas Oncology-Wichita Falls Texoma Cancer Center
Wichita Falls, Texas
Virginia Cancer Specialists, Pc
Arlington, Virginia
Blue Ridge Cancer Care
Roanoke, Virginia
Princess Alexandra Hospital Australia
Woolloongabba, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Monash Medical Centre Clayton
Clayton, Victoria, Australia
Zna Middelheim
Antwerp, Belgium
Ulb Hospital Erasme
Brussels, Belgium
Herlev Og Gentofte Hospital
Herlev, Denmark
Vejle Hospital
Vejle, Denmark
Institut de Cancerologie de L Ouest - Site Paul Papin
Angers, France
Chu Besancon Hospital Jean Minjoz
Besançon, France
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
Centre Leon Berard
Lyon, France
Chu Hopital de La Timone
Marseille, France
Institut Du Cancer de Montpellier
Montpellier, France
Centre Antoine Laccassagne
Nice, France
Hospital Universitaire Pitie-Salpetriere
Paris, France
Hospital de La Miletrie
Poitiers, France
Chu de Rennes - Hospital Pontchaillou
Rennes, France
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume
Rouen, France
Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau
Saint-Herblain, France
Institut de Cancerologie de Strasbourg
Strasbourg, France
Chu Toulouse Hopital Rangueil
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Universitatsklinikum Bonn Aoer
Bonn, Germany
University Clinic Carl Gustav Carus Technical University Dresden
Dresden, Germany
Asklepios Klinik Altona
Hamburg, Germany
Fondazione Irccs Ca Granda Ospedale Maggiore
Milan, Italy
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.